Advanced HIV: Outcomes for Rapid ART

UnknownOBSERVATIONAL
Enrollment

50

Participants

Timeline

Start Date

August 30, 2022

Primary Completion Date

August 30, 2024

Study Completion Date

January 15, 2025

Conditions
HIV-1-infection
Interventions
DRUG

Bictegravir/emtricitabine/tenofovir alafenamide

Patients who are ART-naive adults,18 years of age and older, diagnosed with HIV within 7 days of study entry who have a clinical (diagnosed Opportunistic Infection/AIDS-defining illness) or laboratory (CD4\<200) diagnosis of advanced HIV, who are clinically appropriate for Rapid ART initiation, and are initiated on bic/f/taf per DHHS guidelines at their initial clinic visit will be monitored for time to viral suppression, efficacy and CD4 cell recovery over the course of 48 weeks.

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

Valley AIDS Council

OTHER